Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars

AProgen doubles production capacity with addition of two new perfusion production lines

May 27, 2020

Pulse News reported that AProgen had doubled its production capacity with the addition of two new perfusion production lines, increasing total output capacity to 240,000 litres of culture fluid per cycle. AProgen currently has adalimumab, infliximab, trastuzumab, etanercept, cetuximab and bevacizumab biosimilars under development.

Print Page Mail Article